Genotypically Confirmed Vancomycin-Resistant Staphylococcus aureus With vanB Gene Among Clinical Isolates in...

Area of Science:

• Medical Microbiology
• Infectious Diseases
• Antimicrobial Resistance

Background:

• Staphylococcus aureus is a significant bacterial pathogen.
• Antimicrobial resistance, particularly in MRSA, is a growing global health concern.
• Vancomycin resistance in MRSA complicates treatment strategies.

Purpose of the Study:

• To assess vancomycin susceptibility in S. aureus isolates.
• To detect the presence of key resistance genes (mecA, vanA, vanB) in S. aureus.
• To understand the prevalence of vancomycin resistance mechanisms in clinical isolates.

Main Methods:

• Clinical samples were analyzed for S. aureus identification.
• Antibiotic susceptibility testing was performed using disk diffusion and agar dilution methods.
• Conventional polymerase chain reaction was employed to screen for mecA, vanA, and vanB genes.

Main Results:

• 80 S. aureus isolates were identified from 1245 samples.
• 47.5% of isolates were confirmed as MRSA, with mecA gene detected in 84.2%.
• Vancomycin-intermediate S. aureus (VISA) was found in 10.5% of MRSA isolates; vanA was absent, but vanB was detected in two isolates.

Conclusions:

• The presence of vanB gene indicates a potential spread of vancomycin resistance in S. aureus.
• Urgent implementation of control measures in healthcare settings is crucial to combat vancomycin resistance.
• Continued surveillance and research are necessary to address this public health challenge.